About Riboxx
Riboxx is a company based in Radebeul (Germany) founded in 2009. Riboxx has raised $1.18 million across 3 funding rounds from investors including BMBF and TGFS. The company has 4 employees as of December 31, 2017. Riboxx offers products and services including iVORi siRNA, CONmiR miRNA mimics, RIBOXXOL, and RIGOXXON. Riboxx operates in a competitive market with competitors including GenScript, Parse Biosciences, Dicerna Pharmaceuticals, Sino Biological and Orna, among others.
- Headquarter Radebeul, Germany
- Employees 4 as on 31 Dec, 2017
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Riboxx Gmbh
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.18 M (USD)
in 3 rounds
-
Latest Funding Round
$1.18 M (USD), Seed
Jan 12, 2015
-
Investors
BMBF
& 1 more
-
Employee Count
4
as on Dec 31, 2017
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Riboxx
Riboxx offers a comprehensive portfolio of products and services, including iVORi siRNA, CONmiR miRNA mimics, RIBOXXOL, and RIGOXXON.
siRNA for in vivo gene silencing in research applications.
Mimics for microRNA functions in biological studies.
Ligands for activating immune responses in experiments.
Ligands for RNA-induced immune activation purposes.
Funding Insights of Riboxx
Riboxx has successfully raised a total of $1.18M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $1.18 million completed in January 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Riboxx
Riboxx has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include BMBF and TGFS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and support are provided to technology startups in Saxony.
|
Locked | Locked | Locked | |
|
Education and research policies are overseen by the ministry.
|
Locked | Locked | Locked |
Investor details for Riboxx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Riboxx
Investment portfolio details for Riboxx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Riboxx
Detailed financials for Riboxx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Riboxx Comparisons
Peer comparison for Riboxx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Riboxx
Riboxx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GenScript, Parse Biosciences, Dicerna Pharmaceuticals, Sino Biological and Orna, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Reagents and instruments are provided for life sciences research.
|
|
| Locked | Locked | Locked |
RNA-sequencing transcriptome kits for health data analysis are developed.
|
|
| Locked | Locked | Locked |
Drugs are developed using RNA interference technology platform.
|
|
| Locked | Locked | Locked |
Reagents and kits are provided for clinical research applications.
|
|
| Locked | Locked | Locked |
Technologies for producing circular RNA therapeutics are developed.
|
|
| Locked | Locked | Locked |
Develops tools and products for research and clinical application
|
Detailed competitors of Riboxx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Riboxx
Complete news archive for Riboxx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Riboxx
Riboxx was founded in 2009 and raised its 1st funding round 1 year after it was founded.
Riboxx is headquartered in Radebeul, Germany. It is registered at Radebeul, Saxony, Germany.
Riboxx is a funded company, having raised a total of $1.18M across 3 funding rounds to date.
As of Dec 31, 2017, the latest employee count at Riboxx is 4.
Riboxx was founded in 2009 in Radebeul, Germany, as a provider of siRNA reagents, miRNA mimics, and immunomodulators within the biotechnology sector. Operations are divided into two lines: Riboxx Life Sciences, focused on RNA reagents for life sciences research, and Riboxx Pharma, dedicated to the development and industrial manufacturing of immunomodulators for therapeutic vaccines against cancer and prophylactic vaccines against infections.
Riboxx's top competitors include Sino Biological, Dicerna Pharmaceuticals and Parse Biosciences.
Riboxx offers iVORi siRNA, CONmiR miRNA mimics, RIBOXXOL, and RIGOXXON.